7-Ethyl-10-hydroxycamptothecin: Advancing Topoisomerase I Inhibitor Research
1. Molecular Identity
- Chemical Name: (4S)-4-ethyl-4-hydroxy-10-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
- CAS Number: 86639-52-3
- Source: Semi-synthetic derivative of camptothecin, structurally related to irinotecan
2. Biochemical Significance
7-Ethyl-10-hydroxycamptothecin, also known as SN-38, is the active metabolite of irinotecan. Its potent topoisomerase I inhibitory activity and unique structural features make it a compound of significant interest in cancer research and drug development.
3. Key Research Properties
- Potent Topoisomerase I Inhibition: Exhibits strong activity against DNA topoisomerase I
- Anticancer Potential: Demonstrates high cytotoxicity against various cancer cell lines
- Metabolic Relevance: Key active metabolite of the prodrug irinotecan
- Structure-Activity Insights: Provides valuable data for camptothecin analogue development
4. Potential Research Applications
- Cancer drug development and optimization
- Pharmacokinetic and metabolic studies of irinotecan
- Investigation of topoisomerase I-mediated DNA damage and repair mechanisms
- Development of novel drug delivery systems for improved efficacy
5. Current Research Focus
Ongoing studies are investigating 7-Ethyl-10-hydroxycamptothecin’s effects on:
- Various cancer types, including colorectal and pancreatic cancers
- Overcoming drug resistance mechanisms in cancer therapy
- Nanoformulations and targeted delivery approaches
- Combination therapies with other anticancer agents
6. Formulation Challenges and Innovations
Researchers are actively working on:
- Enhancing solubility and bioavailability
- Developing stable formulations to preserve the active lactone form
- Creating targeted delivery systems for improved tumor specificity
7. Regulatory Considerations
As a metabolite of the approved drug irinotecan, 7-Ethyl-10-hydroxycamptothecin (CAS 86639-52-3) has established safety data. However, its direct use as a therapeutic agent would require additional regulatory approvals and clinical trials.
8. Future Research Directions
The scientific community anticipates:
- Development of novel 7-Ethyl-10-hydroxycamptothecin derivatives and conjugates
- Advanced studies on personalized dosing strategies based on metabolic profiles
- Exploration of its potential in non-cancer applications, such as antiviral research
9. Collaborative Opportunities
We invite researchers, pharmaceutical companies, and academic institutions to explore the research potential of 7-Ethyl-10-hydroxycamptothecin. For inquiries, collaborations, or to discuss how this compound can benefit your research projects, please contact us at sales@nstchemicals.com.
Join us in advancing cancer research with 7-Ethyl-10-hydroxycamptothecin – a crucial compound in the ongoing development of effective topoisomerase I inhibitors.
